Aurelie Millier
Creativ-Ceutical, 215 rue du Faubourg Saint Honoré 75008 Paris,
France
Review Article
Reasons for Aripiprazole Discontinuation in Schizophrenia - A Retrospective
Author(s): Aurelie Millier, Benjamin Briquet, Nadia Georges, Venkatesha Murthy and Mondher ToumiAurelie Millier, Benjamin Briquet, Nadia Georges, Venkatesha Murthy and Mondher Toumi
Objectives: Patients with schizophrenia taking first- or second-generation antipsychotic drugs may switch to
treatment with Aripiprazole due to side effects. This atypical antipsychotic launched in Europe in 2004, and has a
better reported safety profile. However, patients also discontinue Aripiprazole, despite the lack of a comparable
alternative antipsychotic. As very few data are available in the literature, it seems important to investigate the
reasons for Aripiprazole discontinuation.
Methods: A retrospective multicenter observational study of 287 patients with schizophrenia was conducted in
France, Germany and Sweden. Eligible patients were treated with aripiprazole in the last two years and were
switched to another antipsychotic. Their psychiatrists were asked to report online the reasons for discontinuation of
aripiprazol.. View More»
